I spent the weekend with thousands of blood disease researchers. This is what happened.
Juno now finds itself one year, if not two years or more, behind rivals Novartis and Kite.
'We're seeing impressive, early responses with BB2121 without the toxicity,' says Bluebird CEO Nick Leschly.
A successful breakout for these stocks could lead to a large-percentage gain.